Leptomycin B

- Overview
  - Leptomycin B is the dominant member of the Leptomycin class, secondary metabolites isolated from selected Streptomyces strains. It is a bioactive small molecule with antifungal and antibacterial activity. It is a nuclear export inhibitor, targeting chromosome region maintenance 1 (CRM1), a nuclear export receptor and a protein in the nuclear export signal (NES) thus can be used as a tool to study nuclear export. Leptomycin B is an inhibitor of nucleo-cytoplasmic translocation of HIV-1 Rev protein and Rev-dependent mRNA. It has anti-cancer activity and can modulate cancer-specific pathways.
    Leptomycin B is soluble in ethanol and methanol, practically insoluble in water, and unstable in DMSO.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Leptomycin B is a highly specific and potent inhibitor of CRM1 function. It binds irreversibly with the sulfhydryl group of a Cys residue in the cargo biding domaine of CRM1. It affects proteins c-Abl, cyclin B1, HIV-1 Rev, IκB, MPF, MAP/ERK, MDM2/p53, NF-κB/IκB7 and PKA. Leptomycin B inhibits the export of many RNAs (COX-2, cFOS mRNA).
- Properties
  - CAS Number
    
    87081-35-4
    
    Molecular Formula
    
    C33H48O6
    
    Molecular Weight
    
    540.7
    
    Appearance
    
    Colourless Film
    
    Other Properties
    
    Source: Streptomyces spp.
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Microbiology Applications: Leptomycin B is an inhibitor of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. The HIV-1 regulatory protein Rev is required for unspliced and incompletely spliced viral mRNAs to appear in the cytoplasm and thus for viral replication.
    
    Cancer Applications: Leptomycin B can be used as an anti-tumor agent against murine experimental lung cancer tumors using human lung adenocarcinoma epithelial cell lines A549 and NCI-H358 when pretreated with doxorubicin. This was accomplished through activating and restoring p53 and potentially other signaling pathways involving sequestosome 1, showing that Leptomycin B can modulate cancer-specific pathways (Lu et al, 2012).
    Leptomycin B inhibits COX-2 expression induced by serum withdrawal in a human breast cancer cell line MDA-MB-231. LMB may inhibit COX-2 expression by blocking nuclear export of COX-2 mRNA, which may be an important control point of COX-2 gene expression (Jang et al, 2003).